A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
The FDA has finally confirmed the date of a review of Covid vaccine data in the very young, but has Pfizer/Biontech already won the race?